Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31592687 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MTNR1AMTNR1BAOC3PARP1 | |
| SCHEMBL6121064 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MTNR1AMTNR1BAOC3PARP1 | |
| SCHEMBL31505889 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MTNR1AMTNR1BAOC3PARP1 | |
| SCHEMBL9457197 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MTNR1AMTNR1BAOC3PARP1 | |
| SCHEMBL29913554 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MTNR1AMTNR1BAOC3PARP1 | |
| Hydrochloric Acid SCHEMBL28851336 | 0.98 | L3MBTL1 (0.55) | L3MBTL1MTNR1AMTNR1BAOC3PARP1 | |
| SCHEMBL21194008 | 0.91 | L3MBTL1 (0.49) | L3MBTL1MTNR1AMTNR1BAOC3PARP1 | |
| SCHEMBL6120583 | 0.86 | ATM (0.48) | L3MBTL1MTNR1AMTNR1BAOC3TDP1 | |
| SCHEMBL6390839 | 0.86 | L3MBTL1 (0.60) | L3MBTL1MTNR1AMTNR1BAOC3PARP1 | |
| SCHEMBL14032279 | 0.85 | L3MBTL1 (0.55) | L3MBTL1MTNR1AMTNR1BAOC3PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117480161-A | Novel 2, 3-dihydro-1H-pyrrolo [3,2-b ] pyridine derivatives as sigma ligands | 塔拉森调理公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| EP-2640719-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9156823-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156823-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| WO-2012068234-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | L3MBTL1 3251/4885MTNR1A 4239/4885MTNR1B 3697/4885 |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | L3MBTL1 2200/4885MTNR1A 4528/4885MTNR1B 4573/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | L3MBTL1 3251/4885MTNR1A 4239/4885MTNR1B 3697/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | L3MBTL1 3251/4885MTNR1A 4239/4885MTNR1B 3697/4885 |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | L3MBTL1 3771/4885MTNR1A 1059/4885MTNR1B 846/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | L3MBTL1 3251/4885MTNR1A 4239/4885MTNR1B 3697/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | L3MBTL1 4664/4885MTNR1A 1360/4885MTNR1B 682/4885 |
| US-10344019-B2 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | L3MBTL1 2200/4885MTNR1A 4528/4885MTNR1B 4573/4885 |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | L3MBTL1 2200/4885MTNR1A 4528/4885MTNR1B 4573/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | L3MBTL1 2200/4885MTNR1A 4528/4885MTNR1B 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.